GlassScriptPhysician profile
Olivia Mattner
NPI 1831849231
$836.25
in general payments reported to CMS, 2019-2025
12 companies · $518 in 2025
The $518 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20.43 · 2024: $298 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $180.86 | 2024 | Ultomiris |
| Abbvie INC. | $131.15 | 2025 | |
| Ucb, INC. | $126.25 | 2025 | Nayzilam, Fintepla, Rystiggo |
| Amgen INC. | $82.79 | 2024-2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $38.90 | 2025 | Hyqvia |
| Csl Behring | $33.45 | 2025 | Hizentra |
| Neurelis, INC. | $30.79 | 2025 | Valtoco |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.02 | 2025 | Rexulti |
| Tg Therapeutics, INC. | $25.41 | 2025 | |
| Acadia Pharmaceuticals INC | $23.72 | 2025 | Nuplazid |
| Argenx US, INC. | $21.98 | 2025 | Vyvgart Hytrulo |
| Alnylam Pharmaceuticals INC. | $17.08 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Mattner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.